HUYA Bioscience International

OverviewSuggest Edit

HUYA Bioscience International is a company specializing in the biopharmaceutical products. It provides a number of compounds including the oncology drug HBI-8000, the anti-arrhythmic HBI-3000, and the small molecule with regenerative properties for myocardial infarction HBI-3802.
TypePrivate
Founded2004
HQSan Diego, CA, US
Websitehuyabio.com
Employee Ratings2.8
Overall CultureF

Latest Updates

Employees (est.) (Apr 2021)84(+3%)
Cybersecurity ratingBMore

Key People/Management at HUYA Bioscience International

Yung-Chih Wang

Yung-Chih Wang

Senior Vice President, Corporate Development – China
Mireille Gillings

Mireille Gillings

CEO and Executive Chair
Hiroshi Onogi

Hiroshi Onogi

Executive Vice President, Head of Clinical Development, Japan
Gloria Lee

Gloria Lee

Chief Medical Officer
Robert Goodenow

Robert Goodenow

President
Ken Nanami

Ken Nanami

Director, Clinical Operations
Show more

HUYA Bioscience International Office Locations

HUYA Bioscience International has offices in San Diego, Chengdu Shi, Guangzhou Shi, Hangzhou and in 2 other locations
San Diego, CA, US (HQ)
12531 High Bluff Dr #138
Guangzhou Shi, CN
room 204, building 23, 110-1 Xianlie Middle Rd, Yuexiu Qu
Hangzhou, CN
Xiasha District, Jianggan District
Wuhan, CN
Hongshan
Chiyoda City, JP
1-chōme-1-1 Uchisaiwaichō
Show all (9)

HUYA Bioscience International Financials and Metrics

Summary Metrics

Founding Date

2004

HUYA Bioscience International total Funding

$12.6 m

HUYA Bioscience International latest funding size

$7.6 m

Time since last funding

9 years ago
HUYA Bioscience International's latest funding round in April 2012 was reported to be $7.6 m. In total, HUYA Bioscience International has raised $12.6 m
Show all financial metrics

HUYA Bioscience International Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

HUYA Bioscience International Online and Social Media Presence

Embed Graph

HUYA Bioscience International Company Culture

  • Overall Culture

    F

    34/100

  • CEO Rating

    F

    13/100

  • Compensation

    C

    69/100

Learn more on Comparably

HUYA Bioscience International Blogs

HUYABIO International Submits HBI-8000 Monotherapy for Peripheral T-cell Lymphoma for Regulatory Approval in Japan

Represents a second submission for HBI-8000 to treat relapsed/refractory lymphoma San Diego, CA, USA – April 6, 2021 – HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the submission of a regulatory application …

HUYABIO International Announces Global Clinical Trial Collaboration with Bristol Myers Squibb in Melanoma

Global Phase 3 pivotal trial to combine HUYABIO’s HBI-8000 with Opdivo® (nivolumab) in melanoma San Diego, CA, USA – March 30, 2021 – HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a c…

Jay W. Mason, MD

 Dr. Mason has served as a Cardiology consultant to HUYABIO since 2017. He is Professor of Medicine (Cardiology) at the University of Utah, Chief Medical Officer at Spaulding Clinical Research, and an independent consultant in cardiac safety. He obtained his undergraduate degree at Princeton Univers…

HUYABIO International and Tianjin Institute of Pharmaceutical Research Joint Venture Submits Chinese New Drug Application for Efinaconazole as Jublia™

Regulatory filing with China’s National Medical Products Administration requests approval for Jublia for treatment of onychomycosis, a fungal toenail infection. San Diego, CA, USA – March 9, 2021 – HUYABIO International (HUYABIO), the leader in accelerating global development of China’s pharmaceu…

Denis Roy, MD, FRCPC, FHRS

Dr. Roy is a cardiac electrophysiologist and was Chief Executive Officer at the Montréal Heart Institute (2012-2017). He is Professor of Medicine and former Executive Vice-Dean of Medicine at Université de Montréal, and has previously served as President of the Quebec Association of Cardiologists an…

Fred Cohen, MD

Dr. Cohen is a Co-Founder and Senior Managing Director at Vida Ventures. Prior to Vida, he was a Partner and founder of TPG Biotechnology, a life science focused investment effort from 2001-2016. From 1980 through 2014, Dr. Cohen was at UCSF where he held various clinical responsibilities and his…
Show more

HUYA Bioscience International Frequently Asked Questions

  • When was HUYA Bioscience International founded?

    HUYA Bioscience International was founded in 2004.

  • Who are HUYA Bioscience International key executives?

    HUYA Bioscience International's key executives are Yung-Chih Wang, Mireille Gillings and Hiroshi Onogi.

  • How many employees does HUYA Bioscience International have?

    HUYA Bioscience International has 84 employees.

  • Who are HUYA Bioscience International competitors?

    Competitors of HUYA Bioscience International include Ethypharm, Celltrion Healthcare and Pharmacyclics.

  • Where is HUYA Bioscience International headquarters?

    HUYA Bioscience International headquarters is located at 12531 High Bluff Dr #138, San Diego.

  • Where are HUYA Bioscience International offices?

    HUYA Bioscience International has offices in San Diego, Chengdu Shi, Guangzhou Shi, Hangzhou and in 2 other locations.

  • How many offices does HUYA Bioscience International have?

    HUYA Bioscience International has 9 offices.